BE483963A - - Google Patents
Info
- Publication number
- BE483963A BE483963A BE483963DA BE483963A BE 483963 A BE483963 A BE 483963A BE 483963D A BE483963D A BE 483963DA BE 483963 A BE483963 A BE 483963A
- Authority
- BE
- Belgium
- Prior art keywords
- oxyphenyl
- para
- ascorbic acid
- effect
- methylamino
- Prior art date
Links
- 229960005070 ascorbic acid Drugs 0.000 claims description 9
- 239000011668 ascorbic acid Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000001975 sympathomimetic effect Effects 0.000 claims description 3
- 239000000150 Sympathomimetic Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 235000010323 ascorbic acid Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- 229940095064 tartrate Drugs 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000269350 Anura Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 206010062119 Sympathomimetic effect Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000010438 granite Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE483963A true BE483963A (cg-RX-API-DMAC7.html) |
Family
ID=130245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE483963D BE483963A (cg-RX-API-DMAC7.html) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE483963A (cg-RX-API-DMAC7.html) |
-
0
- BE BE483963D patent/BE483963A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0233106B1 (fr) | (-)-Benzhydrylsulfinylacétamide, procédé de préparation et utilisation en thérapeutique | |
| CH643529A5 (fr) | Phenethanolamines. | |
| BE834794A (fr) | Acide 3-trihydroxygermano-propionique | |
| FR2460672A1 (fr) | Preparation de poudre d'acetylsalicylate pour injection | |
| BE483963A (cg-RX-API-DMAC7.html) | ||
| EP0069674A1 (fr) | Médicaments contenant une N-acyl-L-aspartyl-taurine | |
| CH651032A5 (fr) | Phenoxyisobutyrates de moroxydine et medicaments les contenant. | |
| CA2103667C (fr) | Nouvelles compositions liquides a base de derives de la piperidine substitues en 1,4 | |
| CH667656A5 (fr) | Derive de benzodioxepanne et son procede de synthese. | |
| CA1136645A (fr) | Medicaments analeptiques | |
| CH398562A (fr) | Procédé de préparation de l'acide 1-cétocyclododécyl-2-acétique et de ses sels | |
| FR2538805A1 (fr) | Procede de preparation d'halomethylate de levallorphan et composition pharmaceutique antagoniste peripherique des opiaces en contenant | |
| BE566052A (cg-RX-API-DMAC7.html) | ||
| CH627463A5 (en) | Salts of basic amino sugars or of basic amino acids | |
| BE730139A (cg-RX-API-DMAC7.html) | ||
| BE539570A (cg-RX-API-DMAC7.html) | ||
| FR2505336A1 (fr) | Nouveau derive de la 2,4-dioxacyclohexanone, procede de sa preparation et medicaments le contenant | |
| BE557985A (cg-RX-API-DMAC7.html) | ||
| BE784531A (fr) | 1-phenyl biguanides et leur preparation | |
| BE865186A (fr) | Nouvelle forme galenique du bencyclane | |
| BE775377A (fr) | Nouveaux composes polypeptidiques destines au diagnostic de l'hyposecretion d'enzyme pancreatique | |
| BE530472A (cg-RX-API-DMAC7.html) | ||
| BE561273A (cg-RX-API-DMAC7.html) | ||
| BE543611A (cg-RX-API-DMAC7.html) | ||
| BE538014A (cg-RX-API-DMAC7.html) |